請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66219
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林仁混(Jen-Kun Lin) | |
dc.contributor.author | Yea-Tzy Deng | en |
dc.contributor.author | 鄧雅姿 | zh_TW |
dc.date.accessioned | 2021-06-17T00:26:05Z | - |
dc.date.available | 2017-09-19 | |
dc.date.copyright | 2012-09-19 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2012-03-05 | |
dc.identifier.citation | 1. Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 2001, 90, 157-177.
2. Lee J, Huang MS, Yang IC et al. Essential roles of caspases and their upstream regulators in rotenone-induced apoptosis. Biochem Biophys Res Commun 2008, 371, 33-38. 3. Radad K, Rausch WD, Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem Int 2006, 49, 379-386. 4. Lindahl PE, Oberg KE. The effect of rotenone on respiration and its point of attack. Exp Cell Res 1961, 23, 228-237. 5. Ling N. Rotenone.a review of its toxicity and use for fisheries management. Science for Conservation 2003, 211, 211-251. 6. Wolvetang EJ, Johnson KL, Krauer K, Ralph SJ, Linnane AW. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett 1994, 339, 40-44. 7. Isenberg JS, Klaunig JE. Role of the mitochondrial membrane permeability transition (MPT) in rotenone-induced apoptosis in liver cells. Toxicol Sci 2000, 53, 340-351. 8. Isenberg JS, Kolaja KL, Ayoubi SA, Watkins JB, 3rd, Klaunig JE. Inhibition of WY-14,643 induced hepatic lesion growth in mice by rotenone. Carcinogenesis 1997, 18, 1511-1519. 9. Armstrong JS, Hornung B, Lecane P, Jones DP, Knox SJ. Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW. Biochem Biophys Res Commun 2001, 289, 973-978. 10. Tada-Oikawa S, Hiraku Y, Kawanishi M, Kawanishi S. Mechanism for generation of hydrogen peroxide and change of mitochondrial membrane potential during rotenone-induced apoptosis. Life Sci 2003, 73, 3277-3288. 11. Chung WG, Miranda CL, Maier CS. Epigallocatechin gallate (EGCG) potentiates the cytotoxicity of rotenone in neuroblastoma SH-SY5Y cells. Brain Res 2007, 1176, 133-142. 12. Bredesen DE. Apoptosis: overview and signal transduction pathways. J Neurotrauma 2000, 17, 801-810. 13. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ 1992, 45-173. 14. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999, 17, 2941-2953. 15. Tamm I, Schriever F, Dorken B. Apoptosis: implications of basic research for clinical oncology. Lancet Oncol 2001, 2, 33-42. 16. Debatin K. Activation of apoptosis pathways by anticancer treatment. Toxicol Lett 2000, 112-113, 41-48. 17. Shao ZM, Li J, Wu J, Han QX, Shen ZZ, Fontana JA, Barsky SH. Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis, Breast Cancer Res Treat 1999, 53, 263-269. 18. Robertson JD, Orrenius S. Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol 2000, 30, 609-627. 19. Chan PC, Lai JF, Cheng CH, Tang MJ, Chiu CC, Chen HC. Suppression of kinase in ultraviolet irradiation-induced apoptosis by overexpression of focal adhesion Madin-Darby canine kidney cells. J Biol Chem 1999, 274, 26901-26906. 20. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med 1996, 2, 1361-1366. 21. Enari M, Hase A, Nagata S. Apoptosis by a cytosolic extract from Fas-activated cells. EMBO J 1995, 14, 5201-5208. 22. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998, 281, 1305-1308. 23. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998, 281, 1312-1316. 24. Reed JC. Cytochrome c: can't live with it--can't live without it. Cell 1997, 91, 559-562. 25. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81, 807-869. 26. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999, 79, 143-180. 27. Pearson G, Robinson F, Beers Gibson T et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22, 153-183. 28. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298, 1911-1912. 29. Tamura S, Hanada M, Sasaki M, Komaki K, Yonezawa T, Kobayashi T. [Regulation of stress-activated protein kinase signaling pathways by protein phosphatases]. Tanpakushitsu Kakusan Koso 2002, 47, 568-575. 30. Ichijo H, Nishida E, Irie K et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275, 90-94. 31. Armstrong JS, Steinauer KK, Hornung B et al. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ 2002, 9, 252-263. 32. Tamura S, Hanada M, Sasaki M, Komaki K, Yonezawa T, Kobayashi T. Regulation of stress-activated protein kinase signaling pathways by protein phosphatases. Tanpakushitsu Kakusan Koso 2002, 47, 568-575. 33. Ichijo H, Nishida E, Irie K, Ten DP, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275, 90-94. 34. Ito Y, Oh-Hashi K, Kiuchi K, Hirata Y. p44/42 MAP kinase and c-Jun N-terminal kinase contribute to the up-regulation of caspase-3 in manganese-induced apoptosis in PC12 cells. Brain Res 2006, 1099, 1-7. 35. Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol Renal Physiol 2004, 287, F543-F549. 36. Caughlan A, Newhouse K, Namgung U, Xia Z. Chlorpyrifos induces apoptosis in rat cortical neurons that is regulated by a balance between p38 and ERK/JNK MAP kinases. Toxicol. Sci 2004., 78, 125-134. 37. Gomez-Santos C, Ferrer I, Reiriz J, Vinals F, Barrachina M, Ambrosio S. MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res 2002, 935, 32-39. 38. Tikoo K, Lau SS, Monks TJ. Histone H3 phosphorylation is coupled to poly-(ADP-ribosylation) during reactive oxygen species-induced cell death in renal proximal tubular epithelial cells. Mol. Pharmacol 2001, 60, 394-402. 39. Ramachandiran S, Huang Q, Dong J, Lau SS, Monks TJ. Mitogen-activated protein kinases contribute to reactive oxygen species-induced cell death in renal proximal tubule epithelial cells. Chem. Res Toxicol 2002, 15, 1635-1642. 40. Dong J, Ramachandiran S, Tikoo K, Jia Z, Lau SS, Monks TJ. EGFR-independent activation of p38 MAPK and EGFR-dependent activation of ERK1/2 are required for ROS-induced renal cell death. Am J Physiol Renal Physiol 2004, 287, F1049-F1058. 41. Chen M, Bao W, Aizman R, Huang P, Aspevall O, Gustafsson LE., Ceccatelli,S. and Celsi,G. Activation of extracellular signal-regulated kinase mediates apoptosis induced by uropathogenic Escherichia coli toxins via nitric oxide synthase: protective role of heme oxygenase-1. J Infect Dis 2004, 190, 127-135. 42. Sinha D, Bannergee S, Schwartz JH, Lieberthal W, Levine JS. Inhibition of ligand-independent ERK1/2 activity in kidney proximal tubular cells deprived of soluble survival factors up-regulates Akt and prevents apoptosis. J Biol Chem 2004, 279, 10962-10972. 43. Namura S, Iihara K, Takami S, Nagata I, Kikuchi H, Matsushita K, Moskowitz MA, Bonventre JV, Alessandrini A. Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci USA 2001, 98, 11569-11574. 44. Mori T, Wang X, Jung JC, Sumii T, Singhal AB, Fini ME, Dixon CE, Alessandrini A, Lo EH. Mitogen-activated protein kinase inhibition in traumatic brain injury: in vitro and in vivo effects. J Cereb Blood Flow Metab 2002, 22, 444-452. 45. Clausen F, Lundqvist H, Ekmark S, Lewen A, Ebendal T, Hillered L. Oxygen free radical-dependent activation of extracellular signal-regulated kinase mediates apoptosis-like cell death after traumatic brain injury. J Neurotrauma 2004, 21, 1168-1182. 46. Jo SK, Cho WY, Sung SA, Kim HK, Won NH. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 2005, 67, 458-466. 47. Watabe M, Kakeya H, Osada H. Requirement of protein kinase (Krs/MST) activation for MT-21-induced apoptosis. Oncogene 1999, 18, 5211-5220. 48. Telford WG, King LE, Fraker PJ. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry 1992, 13, 137-143. 49. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001, 26, 61-66. 50. Chao DT, Korsmeyer SJ. BCL-2 family: regulators of cell death. Annu Rev Immunol 1998, 16, 395-419. 51. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348, 334-336. 52. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995, 7, 541-546. 53. Antonsson B, Conti F, Ciavatta A et al. Inhibition of Bax channel-forming activity by Bcl-2. Science 1997, 277, 370-372. 54. Wesierska-Gadek J, Gueorguieva M, Horky M. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol 2003, 55, 895-902. 55. Ubezio P, Civoli F. Flow cytometric detection of hydrogen peroxide production induced by doxorubicin in cancer cells. Free Radic Biol Med 1994;16:509-516. 56. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000, 103, 239-252. 57. Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Annu Rev Neurosci 1997, 20, 245-267. 58. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281, 1322-1326. 59. Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 1998, 3, 697-707. 60. Fan Y, Chen H, Qiao B et al. Opposing effects of ERK and p38 MAP kinases on HeLa cell apoptosis induced by dipyrithione. Mol Cells 2007, 23, 30-38. 61. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1997, 1333, F85-104. 62. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270, 1326-1331. 63. Raingeaud J, Gupta S, Rogers JS et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270, 7420-7426. 64. Wang ZY, Huang MT, Ferraro T., Wong CQ, Lou YR, Reuhl K, Iatropoulos M, Yang CS, Conney AH. Inhibitory effect of green tea in the drinking water on tumorigenesis by ultraviolet light and 12-O-tetradecanoylphorbol-13-acetate in skin of SKH-1 mice. Cancer Res 1992, 52, 1162-1170. 65. Shiraki M, Hara Y, Osawa T, Kumon H, Nakauama T, Kawakishi S. Antioxidative and antimutagenic effects of theaflavins from black tea. Mutat Res 1994, 323, 29-34. 66. Yen GC, Chen HY. Antioxidant activity of various tea extracts in relation to their antimutagenicity. J Agric Food Chem 1995, 43, 27-32. 67. Jain AK, Shimoi K, Nakamura Y, Kada T, Hara Y, Tomita I. Crude tea extracts decrease the mutagenic activity of N-methyl-N-nitro-N-nitrosoguanidine in vitro and in intragastric tract of rats. Mutat Res 1989, 210, 1-8. 68. Nihal M, Ahmad N, Mukhtar H, Wood GS. Antiproliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 2005, 114, 513-521. 69. Naasani I, Oh-Hara T, Feng WY, Johnston J, Chan J, Tsuruo T. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res 2003, 63, 824-830. 70. Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ, Varilek GW. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 2001, 60, 528-533. 71. Bhimani RS, Troll W, Grunberger D, Frenkel K. Inhibition of oxidative stress in Hela cells by chemoproventive agents. Cancer Res. 1993, 53, 4528-4533. 72. Ho CT, Chen Q, Shi H, Zhang KQ, Rosen RT. Antioxidative effect of polyphenol extract prepared from various Chinese teas. PreV Med 1992, 21, 520-525. 73. Yoshino K, Hara Y, Sno M, Tomita I. Antioxidatiive effects of black tea theaflavins and thearubigin on lipid peroxidation of rat liver homogenates induced by tertbutyl hydroperoxide. Biol Pharm Bull 1994, 17, 146-149. 74. Katiyar SK, Agarwal R, Mukhtar H. Inhibition of spontaneous and photoenhance lipid peroxidation in mouse epidermal microsomes by epicatechin derivatives from green tea. Cancer Lett 1994, 79, 61-66. 75. Yen GC, Chen HY. Antioxidant activity of various tea extracts in relation to their antimutagenicity. J Agric Food Chem 1995, 43, 27-32. 76. Serafini M, Ghiselli A, Ferro Luzzi A. In vivo antioxidant effect of green and black tea in man. Eur J Clin Nutr 1996, 50, 28-32. 77. Liang YC, Lin-Shiau SY, Chen CF, Lin JK. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997, 67, 55-65. 78. Weng MS, Ho YS, Lin JK. Chrysin induces G1 phase cell cycle arrest in C6 glioma cells through inducing p21 Waf1/Cip1 expression: involvement of p38 mitogen- activated protein kinase. Biochem Pharmacol 2005, 69, 1815-1827. 79. Lin YL, Lin JK. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappa B. Mol Pharmacol 1997, 52, 465-472. 80. Yeh CW, Chen WJ, Chiang CT, Lin-Shiau SY, Lin JK. Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects. Pharmacogenomics J 2003, 3,267-276. 81. Lee HH, Ho CT, Lin JK. Theaflavin-3,3’-digallate and penta-O-galloyl- beta-D-glucose inhibit rat liver microsomal 5alpha-reductase activity and the expression of androgrn receptor in LNCaP prostate cancer cells. Carcinogenesis 2004, 25, 1109-1118. 82. Way TD, Kao MC, Lin JK. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpression breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 2004, 279, 4479-4489. 83. Way TD, Lee HH, Kao MC, Lin JK. Black tea polyphenol theaflavins inhibit aromatase activity and attenuate tamoxifen resistance in HER2/neu-transfected human breast cancer cells through tyrosine kinase suppression. Eur J Cancer 2004, 40, 2165-2174. 84. Lin JK, Lin CL, Liang YC, Lin-Shiau SY, Juan I-Ming. Survey of catechins, gallic acid and methylxanthines in green, oolong, pu-erh and black teas. J Agric Food Chem 1998, 46, 3635-3642. 85. Ji BT, Chow WH, Hsing AW, McLaughlin JK, Dai Q, Gao YT, Blot W, Fraumeni JF. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 1997, 70, 255-258. 86. Yamane T, Nakatani H, Kikuoka N, Matsumoto H, Iwata Y, Kitao Y, Oya K, Takahashi T. Inhibitory effects and toxicity of green tea polyphenols for gastrointestinal carcinogenesis. Cancer 1996, 77, 1662-1667. 87. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993, 85, 1038-1049. 88. Dona M, Dell'Aica I, Calabrese F, Benelli R, Morini M, Albini A, Garbisa S. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol 2003, 170, 4335-4341. 89. Kundu JK, Na HK, Chun KS, Kim YK, Lee SJ, Lee SS, Lee OS, Sim YC, Surh YJ. Inhibition of phorbol ester-induced COX-2 expression by epigallocatechin gallate in mouse skin and cultured human mammary epithelial cells. J Nutr 2003, 133, 3805S-3810S. 90. Roy M, Chakrabarty S, Sinha D, Bhattacharya RK, Siddiqi M. Anticlastogenic, antigenotoxic and apoptotic activity of epigallocatechin gallate: a green tea polyphenol. Mutat Res 2003, 523-524, 33-41. 91. Hirsch FR, Lippman SM. Advances in the biology of lung cancer chemoprevention. J Clin Oncol 2005, 23, 3186-3197. 92. Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004, 10, 4266s-4269s. 93. Kim ES, Hong WK, Khuri FR. Prevention of lung cancer. The new millennium. Chest Surg Clin N Am 2000, 10, 663-690. 94. Li GX, Chen YK, Hou Z, Xiao H, Jin H, Lu G, Lee MJ, Liu B, Guan F, Yang Z, Yu A, Yang CS. Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis 2010, 31, 902-910. 95. Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Carroll JL, Williams BJ, Cardelli JA. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 2009, 15, 4885-4894. 96. Shim JH, Su ZY, Chae JI, Kim DJ, Zhu F, Ma WY, Bode AM, Yang CS, Dong Z. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev Res (Phila Pa) 2010, 3, 670-679. 97. Yamauchi R, Sasaki K, Yoshida K. Identification of epigallocatechin-3-gallate in green tea polyphenols as a potent inducer of p53-dependent apoptosis in the human lung cancer cell line A549. Toxicol In Vitro 2009, 23, 834-839. 98. Sadava D, Whitlock E, Kane SE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun 2007, 360, 233-237. 99. Kweon MH, Adhami VM, Lee JS, Mukhtar H. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem 2006, 281, 33761-33772. 100. Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008, 19, 52-60. 101. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89, 1260-1270. 102. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000, 6, 149-156. 103. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17, 463-516. 104. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18, 1135-1149. 105. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000, 6, 790-797. 106. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99, 157-166. 107. Liotta LA, Abe S, Robey PG, Martin GR. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci U S A 1979, 76, 2268-2272. 108. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270, 5331-5338. 109. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002, 3, 409-421. 110. Hong C, A.Kim H, L.Firestone G, F.Bjeldanes L. 3,3’-Diindolylmethane (DIM) induces a G1 cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21 WAF1/CIP1 expression. Carcinogenesis 2002, 23, 1297-1305. 111. Chen WJ, Chang CY, Lin JK. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27 Kip and p21 Cip. Biochem Pharmacol 2003, 65, 1777-1785. 112. Liang YC, Lin-Shiau SY, Chen CF, Lin JK. Inhibition of cyclin-dependent kinase 2 and 4 activities as well as induction of cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate. J Cell Biochem 1999, 75, 1-12. 113. Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R, Wu CW. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997, 17, 353-360. 114. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000, 60, 4629-4637. 115. Kuo WH, Yang SF, Chu SC, Lu SO, Chou FP, Hsieh YS. Differential inductions of matrix metalloproteinase-2 and -9 in host tissues during the growth of ascitic sarcoma 180 cells in mice. Cancer Lett 2003, 189, 103-112. 116. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem 2003, 88, 885-898. 117. Pages G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F, Pouyssegur J. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci 2000, 902, 187-200. 118. Uchida C, Gee E, Ispanovic E, Haas TL. JNK as a positive regulator of angiogenic potential in endothelial cells. Cell Biol Int 2008, 32, 769-776. 119. Boyd PJ, Doyle J, Gee E, Pallan S, Haas TL. MAPK signaling regulates endothelial cell assembly into networks and expression of MT1-MMP and MMP-2. Am J Physiol Cell Physiol 2005, 288, C659-C668. 120. Lee YC, Lin HH, Hsu CH, Wang CJ, Chiang TA, Chen JH. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via down-regulation of PI3K/Akt signaling pathway. Eur J Pharmacol 2010, 632, 23-32. 121. Sil H, Sen T, Moulik S, Chatterjee A. Black tea polyphenol (theaflavin) downregulates MMP-2 in human melanoma cell line A375 by involving multiple regulatory molecules. J Environ Pathol Toxicol Oncol 2010, 29, 55-68. 122. Lee SJ, Sakurai H, Oshima K, Kim SH, Saiki I. Anti-metastatic and anti-angiogenic activities of a new matrix metalloproteinase inhibitor, TN-6b. Eur J Cancer 2003, 39, 1632-1641. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66219 | - |
dc.description.abstract | 中文摘要
癌症目前對全世界仍是一大威脅,更是台灣持續蟬聯十大死因的頭號殺手,因此,探討癌症的預防及治療方法仍是科學家孜孜不倦的課題。癌細胞由於具有持續增生及切割細胞外基質進而通過血管進入血液而轉移至其它組織的特性,因此,如何使細胞不再不斷增生及如何抑制細胞轉移至其他組織乃為癌症研究的首要目標。目前已有許多研究報告指出,植物中具有許多可以抑制癌細胞生長及轉移的天然物質,且由於癌症治療須耗費大量金錢,也因此,研究如何利用這些大自然天然的寶藏對抗人類的癌症疾病實為當務之急。魚藤酮存在於魚藤植物的根部,其會抑制粒線體內膜上電子傳遞鏈複合體 Ι (electron transfer chain complex Ι)造成細胞內活性氧 (reactive oxygen species; ROS) 的產生。魚藤酮最早於1930年代開始用來毒魚,於約150年前開始用於當作殺蟲劑。然而近年來的文獻指出,魚藤酮會引起黑色素瘤、白血病細胞凋亡。由於引起細胞凋亡乃為對抗癌細胞之重要步驟,又乳癌為威脅女性之惡性腫瘤,因此,我們極欲探討魚藤酮是否可引起乳癌細胞之細胞凋亡。在本論文中,我們利用methylthiazolyldiphenyl-tetrazolium bromide (MTT)試驗、trypan blue exclusion assay、alamar blue試驗、流式細胞儀、螢光顯微鏡觀察細胞核法,發現魚藤酮可引起人類乳癌細胞株MCF-7發生細胞凋亡的現象,此種結果隨著魚藤酮劑量和時間的增加而更明顯。進一步用西方點墨法分析和引起細胞凋亡現象有關的蛋白發現,魚藤酮可促使poly (ADP-ribose) polymerase (PARP) 活化、抗細胞凋亡現象的蛋白Bcl-2 表現下降、及促進細胞凋亡現象發生的蛋白Bax表現上升,並由觀察魚藤酮對粒線體膜電位的影響發現魚藤酮可改變粒線體膜電位差,更證實了魚藤酮確實會引起MCF-7細胞發生細胞凋亡。由於魚藤酮會抑制電子傳遞鏈複合體 Ι 而導致活性氧產生,我們發現隨著處以MCF-7細胞的魚藤酮濃度增高,確實會增加活性氧的產生。進一步利用西方點墨法研究魚藤酮於MCF-7細胞引起細胞凋亡所經過的訊息傳遞途徑,發現魚藤酮引起的活性氧增加會活化c-jun N-terminal kinase (JNK) 及p38 mitogen-activated protein kinase (p38 MAPK) 訊息傳遞,並降低extracellular signal-regulated protein kinase 1/2 (ERK 1/2) 訊息傳遞,進而引起細胞凋亡現象的發生。 另一方面,由於癌細胞轉移會導致癌症治療無法順利進行,因此研究如何抑制癌細胞轉移乃為癌症研究之重要課題。轉移是惡性程度高且預後差的癌症之特性,轉移的一個重要步驟是細胞分泌蛋白酶以切割細胞外的基質,使細胞能通過細胞外基質進入血液中,進而隨著血液轉移至其它組織。因此,促使過量細胞外基質的切割是癌細胞轉移的重要特徵,而扮演切割細胞外基質重要角色的是基質蛋白酶 (matrix metalloproteinases; MMPs)。由於肺癌持續為全世界致死率最高的癌症,且肺癌的高致死率是因其極具轉移的特性,因此我們選用具高轉移能力的肺癌細胞株CL1-5作為研究對象。又茶具有抗癌活性,因此,我們想探究綠茶中主要的茶多酚epigallocatechin-3-gallate (EGCG)是否可抑制高轉移性肺癌細胞株CL1-5轉移的能力。首先利用MTT試驗觀察EGCG對CL1-5細胞生長的影響,發現EGCG濃度高於20 μM時會抑制細胞生長,EGCG濃度於20 μM以下時細胞生長則無明顯影響。進一步探討EGCG於20 μM以上細胞生長的減緩是由於引起細胞凋亡或導致細胞週期停止,以流式細胞儀觀察的結果,EGCG於20 μM以上會導致細胞週期停止於G2時期,且並不會引起細胞凋亡現象的發生。接下來欲探討EGCG對CL1-5細胞轉移能力影響,利用轉移試驗發現EGCG 可抑制CL1-5細胞的轉移能力。由於MMP-2為降解細胞外基質的重要酵素,因此,若MMP-2的表現被抑制,則可抑制細胞降解細胞外基質的能力,進而抑制細胞轉移至其他組織。利用gelatin zymography、西方點墨法、聚合酶連鎖反應,發現EGCG會抑制CL1-5細胞內MMP-2 mRNA及蛋白的表現。進一步研究其中參與的訊息傳遞途徑,發現EGCG會抑制CL1-5細胞內JNK的訊息傳遞,導致MMP-2的轉錄因子NF-κB及Sp1無法由細胞質進入細胞核內進行MMP-2 mRNA的轉錄,而抑制MMP-2 mRNA的形成。觀察EGCG對MMP-2 promoter活性的影響,更證實了EGCG可抑制CL1-5細胞MMP-2 promoter的活性。又因臨床用藥docetaxel具有強副作用如白血球過低、貧血、腹瀉、掉髮,疲倦、虛弱等,因此,我們想探知並用臨床用藥及EGCG是否可減少臨床用藥劑量以期減少副作用的發生,結果指出並用docetaxel與EGCG可在較低劑量的docetaxel即可抑制MMP-2的表現。綜合我們的研究指出,茶中的EGCG及魚藤植物的魚藤酮對癌症預防扮演重要角色! | zh_TW |
dc.description.abstract | Cancer is still a serious problem in the world. Therefore, it is important to find ways to prevent or cure cancer. Because cancer cells possess abilities to prolong cell growth and invade to other tissues, it is still thorny to control cancer disease. Therefore, how to suppress cell growth in cancer cells and prevent cancer cells invade to other tissues is of great urgency. Phytochemicals are a group of compounds from natural plants. Recent reports show that they are bioactive components in natural plant to execute chemoprevention or other beneficial effects such as prevent diabetes, protect neuron cells and prevent obesity. Rotenone is a phytochemical from the roots of the Derris and Lonchorcarpus species. Rotenone is an inhibitor of electron transfer chain complex Ι (NADH dehydrogenase complex) and it can promote production of reactive oxygen species (ROS). It has been used as a botanical insecticide for at least 150 years to control crop pests and used even longer as a fish poison by native tribes in South America and East Africa. Recent reports show that rotenone can induce apoptosis in human melanoma cells and leukemia cells. Because anti-apoptosis plays an important role in anti-cancer, we want to determine whether rotenone can induce apoptosis in MCF-7 breast cancer cells which threaten women worldwide. In this study, we found that rotenone can induce apoptosis in MCF-7 human breast cancer cells by using MTT assay, trypan blue exclusion assay, alamar blue assay, flow cytometry and Hoechst 33258 staining and they are dose- and time-dependent effects. To further confirm these results, we used western blot analysis to investigate apoptosis-related proteins, PARP, Bcl-2 and Bax. We showed that rotenone can promote PARP cleavage, downregulate anti-apoptotic Bcl-2 and upregulate apoptotic Bax. In addition, rotenone can reduce mitochondria membrane potential. Because rotenone is attributed to irreversible binding and inactivation of mitochondrial electron transport chain complex Ι, we investigated whether rotenone indeed promote production of ROS in MCF-7 cells. Rotenone can result in an increase of the reactive oxygen species (ROS). We treated MCF-7 cells with rotenone and indeed found that ROS was increased. Then, we want to determine the signaling pathways under treatment of EGCG in MCF-7 cells. Using western blotting analysis, we found that rotenone induced JNK and p38 activation, whereas it attenuated ERK1/2 activation. Then, apoptosis was induced.
In addition, metastasis is a fundamental property of high malignant cancer cells with poor clinical outcome. Therefore, to investigate how to suppress metastasis is an important urgency. Cleavage of extracellular matrix to allow cells invade into blood and transfer to other tissues is an important step in metastasis and MMPs play important roles in this step. Because lung cancer has the highest rate of cancer mortality worldwide and the highest rate of lung cancer mortality is due to their high potential of metastasis, we used highly invasive CL1-5 human lung cancer cells to investigate possible mechanisms of suppression tumor invasion in cancer cells. Green tea contains anti-cancer effects, so we want to determine whether EGCG, the major bioactive compound in green tea, can attenuate metastasis in highly invasive CL1-5 human lung cancer cells. First, we found that EGCG suppress cell growth at concentration higher than 20 μM by using MTT assay. Further, we want to investigate whether EGCG induce apoptosis or cell cycle arrest at concentrations higher than 20 μM. We used flow cytometry analysis and found that EGCG induced G2/M arrest in CL1-5 cells at concentrations of 30, 40 and 50 μM. Next, we want to investigate whether EGCG can attenuate invasion ability of CL1-5 cells. Using transwell invasion assay, EGCG could suppress invasion of CL1-5 cells. Because MMP-2 plays important roles to degrade extracellular matrix and is closely related to invasion in patients of lung cancer, we want to investigate whether EGCG can affect expression of MMP-2 in CL1-5 cells. Using gelatin zymography, western blot analysis and PCR, we found that EGCG can repress MMP-2 expression at the transcriptional level. Furthermore, by western blot analysis we showed that EGCG could suppress activation of JNK and attenuate translocation of MMP-2 transcription factor, NF-κB and Sp1, from the cytosol into the nucleus. In addition, docetaxel, a clinical drug used in the treatment of lung cancer, performs serious side effect, we want to clarify synergistic effects of EGCG and docetaxel. Combine EGCG and docetaxel can repress MMP-2 expression at low dosages of docetaxel. Taken together, rotenone and EGCG may be potential phytochemicals to chemoprevent breast cancer and lung cancer respectively and they may play synergistic effects with clinical drug. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T00:26:05Z (GMT). No. of bitstreams: 1 ntu-101-D97442001-1.pdf: 17916286 bytes, checksum: 4bb8df79c3d37c78e7579d74d8a07882 (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 中文摘要…………………………………………i
Abstract…………………………………………v Abbreviations…………………………………ix Table of Contents……………………………xi Chapter 1 Overview………………………………………………………………….1 Chapter 2 Rotenone induces apoptosis in MCF-7 human breast cancer cell-mediated ROS through JNK and p38 signaling……………………………….5 2.1 Summary…………………………… 6 2.2 Introduction………………………7 2.3 Materials and Methods…………12 2.4 Results………………………17 2.5 Discussion…………………………25 2.6 List of figures…………………28 Chapter 3 EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest……………………………………………51 3.1 Summary……………………………………52 3.2 Introduction………………………………53 3.3 Materials and Methods……………………57 3.4 Results………………………………………66 3.5 Discussion…………………………………74 3.6 List of figures…………………………78 References………………………………………104 List of publications…………………………122 Appendix…………………………………………124 | |
dc.language.iso | en | |
dc.title | 魚藤酮引起MCF-7乳癌細胞凋亡及兒茶素抑制CL1-5肺癌細胞轉移之機制探討 | zh_TW |
dc.title | Mechanisms of Rotenone-induced Apoptosis in MCF-7 Human Breast Cancer Cells and Inhibition Effects of EGCG on Metastasis in CL1-5 Human Lung Cancer Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 蕭水銀,李明學,林榮耀,鍾景光,何元順 | |
dc.subject.keyword | 魚藤酮,細胞凋亡,活性氧,EGCG,細胞轉移,細胞週期, | zh_TW |
dc.subject.keyword | rotenone,apoptosis,ROS,EGCG,metastasis,cell cycle, | en |
dc.relation.page | 124 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-03-05 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生物化學暨分子生物學研究所 | zh_TW |
顯示於系所單位: | 生物化學暨分子生物學科研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 17.5 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。